Work

783TiP Phase I study of HFB301001, a novel OX40 agonist monoclonal antibody, in patients with solid tumors selected via Drug Intelligence Science (DIS)

Year: 2022

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2022.07.909

Authors: A. Spira, R. Mehra, C. Mantia, H. Babiker, M. Borad, A. Cervantes, E. Garralda, A. Mahipal, L. Paz-Ares, C. Hatzis, A. Liu, A. Raue, J. Gan, F. Adrian, L. Manenti, A.B. El-Khoueiry

Institutions: Virginia Cancer Specialists, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Dana-Farber Cancer Institute, Mayo Clinic in Florida, Mayo Clinic Comprehensive Cancer Center (Florida), Mayo Clinic, Mayo Clinic in Arizona, Hospital Clínico Universitario de Valencia, Vall d'Hebron Hospital Universitari, Hospital Universitario 12 De Octubre, University of Southern California

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4295817501

FWCI: 0.181

Cites: 1

Cited by: 5

Related to: 10